Central Venous Catheterization News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Peripheral IV Access for Chemo Better Than Central Lines in Testicular Cancer?
(MedPage Today) -- Patients with testicular cancer had fewer venous access-related complications and overall thrombotic events when first-line chemotherapy was delivered via peripheral intravenous access compared with central venous access devices... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 30, 2024 Category: Hematology Source Type: news
New data reinforce the benefit of early preventative treatment with Roche ’s Hemlibra for babies with severe haemophilia A
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with ha...
Source: Roche Investor Update - December 9, 2023 Category: Pharmaceuticals Source Type: news
New data reinforce the benefit of early preventative treatment with Roche ’s Hemlibra for babies with severe haemophilia A
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with ha...
Source: Roche Media News - December 9, 2023 Category: Pharmaceuticals Source Type: news
Study Weighs Timing of Platelet Transfusion With Central Venous Catheter Placement
FRIDAY, May 26, 2023 -- For patients with severe thrombocytopenia, withholding of prophylactic platelet transfusion before ultrasound-guided placement of a central venous catheter (CVC) results in more CVC-related bleeding events than prophylactic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 26, 2023 Category: Pharmaceuticals Source Type: news
Central venous catheter contamination rate in suspected sepsis patients - an observational clinical study
Conclusion: Although only a minority of CLABSI-suspect patients had positive blood cultures, the contamination rate of central venous catheters and administration set was high, possibly indicating a relevant under-reporting. The finding of identical species in adjacent segments underlines the role of upward or downward spread of microorganisms within the tubes, therefore aseptic tasks should be emphasized. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 14, 2023 Category: Consumer Health News Source Type: news
Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningful bleed control in infants from birth
The HAVEN 7 studywas designed to further confirm the benefit of preventative treatment (prophylaxis) withHemlibra from birth in previously untreated or minimally treated infants with severehaemophilia A without inhibitorsIn the study, 77.8% of participants had no bleeding episodes that required treatment1In addition, real-world efficacy and safety data from the EUHASS database and ATHN 7 study were also presented2,3Basel, 11 December 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim results from the phase III HAVEN 7 study. The study shows Hemlibra® (emicizumab) achieved meaningful bleed control with a ...
Source: Roche Media News - December 11, 2022 Category: Pharmaceuticals Source Type: news
Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningful bleed control in infants from birth
The HAVEN 7 studywas designed to further confirm the benefit of preventative treatment (prophylaxis) withHemlibra from birth in previously untreated or minimally treated infants with severehaemophilia A without inhibitorsIn the study, 77.8% of participants had no bleeding episodes that required treatment1In addition, real-world efficacy and safety data from the EUHASS database and ATHN 7 study were also presented2,3Basel, 11 December 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim results from the phase III HAVEN 7 study. The study shows Hemlibra® (emicizumab) achieved meaningful bleed control with a ...
Source: Roche Investor Update - December 11, 2022 Category: Pharmaceuticals Source Type: news
Probiotics in the ICU Linked to Higher Risk of Central Line Infections, Death
(MedPage Today) -- NASHVILLE, Tenn. -- Among patients with central venous catheters in the intensive care unit (ICU), use of probiotic medications was associated with an increased incidence of central line infections and death, a retrospective... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 19, 2022 Category: Gastroenterology Source Type: news
Chlorhexidine (di)gluconate locking device for central line infection prevention in intensive care unit patients: a multi-unit, pilot randomized controlled trial
Conclusions: Using a device that delivers CHG into CVADs was feasible in the ICU. Findings from this trial will inform a full-scale randomized controlled trial and provide preliminary data on the effectiveness of CHGLS. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 20, 2022 Category: Consumer Health News Source Type: news
Clinical characteristics and risk factors associated with ICU-acquired infections in sepsis: A retrospective cohort study
Conclusions: ICU-acquired infections increase the likelihood of septic mortality. The individualized prognostic model on the basis of the nomogram could accurately predict ICU-acquired infection and optimize management or tailored therapy. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 5, 2022 Category: Consumer Health News Source Type: news
Tunneled dialysis line-associated hemorrhagic shock following self-inflicted trauma in a hemodialysis patient: a case report - Bogdan L, Malavade T.
Complications of tunneled central venous catheters (CVCs) for hemodialysis are frequent, and most commonly include bacteremia, thrombosis, and stenosis. While bleeding is a relatively rare complication of dialysis lines overall, tunneled CVCs may present a... (Source: SafetyLit)
Source: SafetyLit - June 27, 2022 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news
Society to Cells / Research News
.ReadMsgBody{
width:100%;
background-color:#ffffff;
}
.ExternalClass{
width:100%;
background-color:#ffffff;
}
.ExternalClass,.ExternalClass p,.ExternalClass span,.ExternalClass font,.ExternalClass td,.ExternalClass div{
line-height:100%;
}
html{
width:100%;
}
body{
-webkit-text-size-adjust:none;
-ms-text-size-adjust:none;
margin:0;
padding:0;
}
table{
border-spacing:0;
border-collapse:collapse;
}
img{
display:block !important;
}
table td{
border-collapse:collapse;
}
.yshortcuts a{
border-bottom:none !important;
}
a{
color:#E03C31;
...
Source: Johns Hopkins University and Health Systems Archive - June 15, 2022 Category: Nursing Source Type: news
POCUS Measure of JVP Predicts Elevated CVP in Heart Failure
TUESDAY, Dec. 28, 2021 -- For patients undergoing right heart catheterization, point-of-care ultrasonography assessment of the jugular venous pressure (JVP) height can accurately predict elevated central venous pressure (CVP), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 28, 2021 Category: Pharmaceuticals Source Type: news
ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infection - Medical technologies guidance (MTG62)
ClearGuard HD antimicrobial barrier caps are recommended as a cost-saving option for preventing catheter-related bloodstream infections in people with central venous catheters having haemodialysis. Data should be collected on any long-term effect of chlorhexidine exposure. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 14, 2021 Category: Consumer Health News Source Type: news
Salvage of Central Venous Catheter Often Successful in Children With CLABSI Salvage of Central Venous Catheter Often Successful in Children With CLABSI
Central venous catheter salvage is often attempted and successful in ambulatory children presenting with central-line-associated bloodstream infections (CLABSIs), according to a new study.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 19, 2021 Category: Intensive Care Tags: Pediatrics News Source Type: news
